Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
03 mai 2022 08h00 HE
|
Imago Biosciences, Inc.
Interim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and...
Global Autologous Cell Therapy Product Market ($ 34.8 Bn by 2028) Growth Forecast at 17.1% CAGR During 2022 to 2028 COVID-19 Impact and Global Analysis by Vantage Market Research
04 mars 2022 03h40 HE
|
Vantage Market Research
WASHINGTON, March 04, 2022 (GLOBE NEWSWIRE) -- Recently, the Autologous Cell Therapy Product Market is changing the face of the medicinal treatment and therapeutics. The major factors driving the...
BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells
04 janv. 2022 06h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies,...
Imago BioSciences to Host Virtual Investor Event
01 déc. 2021 08h00 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new...
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
11 nov. 2021 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
10 nov. 2021 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the...
LGVN SHAREHOLDER ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN
01 nov. 2021 19h45 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or...
United States Biobanks Markets Analysis & Forecasts, 2016-2020 & 2021-2026
24 sept. 2021 06h58 HE
|
Research and Markets
Dublin, Sept. 24, 2021 (GLOBE NEWSWIRE) -- The "United States Biobanks Market, By Type (Population Based Biobanks v/s Disease Oriented Biobanks), By Ownership, By Product, By Specimen Type, By...
Global $15.52 Bn Cell Isolation (Human Cells and Animal Cells) Markets, Competition Forecast & Opportunities, 2026
18 juin 2021 06h13 HE
|
Research and Markets
Dublin, June 18, 2021 (GLOBE NEWSWIRE) -- The "Global Cell Isolation Market By Product (Consumables and Instruments), By Cell Type (Human Cells and Animal Cells), By Source, By Technique, By...
Excellthera and Ossium Health Announce a Collaboration to Advance Their Technologies and Platforms to Improve Human Health
21 avr. 2021 08h02 HE
|
ExCellThera
MONTREAL, April 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells...